Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2014

View Archived Issues

Korean group prepares new monoclonal antibodies

Cedars-Sinai begins phase I trial of brain cancer vaccine

Venaxis completes enrollment in pivotal U.S. trial of APPY1 Test for appendicitis

GERD linked to FOXF1 and MHC locus gene polymorphisms

Researchers at Esteve design novel sigma1 receptor ligands

Tekmira commences phase I trial of TKM-100802

New casein kinase 2 inhibitors disclosed by Bristol-Myers Squibb

Genentech and Roche disclose new ROR-gamma modulators

PARSiFAL trial to investigate BAY-1067197 in heart failure

Mallinckrodt begins patient recruitment in phase I trial of MP-3549.1 in advanced solid tumors

Patient recruitment begins in phase I trial of Ribological's personalized anticancer vaccine

Transgene prepares novel tuberculosis vaccines

DioGenix discloses new data supporting efficacy of multiple sclerosis assay

Maruho to take over marketing rights for Protopic ointment in Japan

Data presented from AIMSPRO study in diffuse systemic sclerosis

OncoCyte commences clinical development of bladder cancer diagnostics in U.S. and China

Alcobra reports promising results from new study of MG-01CI in animal model of fragile X syndrome

Phase I study of A*STAR and Cytos' H1N1 influenza vaccine meets primary immunogenicity endpoint

FDA committee recommends approval of Ragwitek BLA

Amgen's LAPLACE-2 phase III trial of evolocumab in combination with statins meets primary endpoints

Oncolys BioPharma commences phase I/II trial of Telomelysin in Korea and Taiwan

Sosei offers development update on glycopyrronium bromide programs

VCN Biosciences to advance VCN-01 oncolytic adenovirus to clinic

PARP-1 inhibitors developed at Lupin

Astellas reports melatonin agonists for urinary incontinence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...